A 15-year-old’s decade-long quest for a diagnosis ends with a rare genetic discovery
Oliver Broner, now 15, spent over a decade seeking answers for his movement disorders after early developmental delays and a misdiagnosis of cerebral palsy. A rare mutation in the DNM1L gene, initially dismissed as insignificant, was eventually confirmed as the cause through genetic research and fruit fly studies. The condition, affecting only 58 known cases worldwide, is now being managed with medication that has significantly improved his mobility and quality of life.
Key points
- Oliver Broner’s parents noticed stalled developmental milestones and unsteady gait in infancy, but pediatricians initially dismissed their concerns as normal variation.
- After years of misdiagnoses, including cerebral palsy, a 2019 consultation with a geneticist at Texas Children’s Hospital led to whole exome sequencing, which identified a de novo variation in the DNM1L gene.
- The DNM1L gene mutation was initially classified as having 'unknown significance' but was later reclassified as 'likely pathogenic' after research on fruit flies confirmed its impact on mitochondrial function and movement.
- Oliver’s symptoms improved significantly after being prescribed Sinemet (levodopa-carbidopa), a Parkinson’s disease medication, which helped stabilize his gait and reduce pain.
- The Broner family has since launched a foundation to support research and connect the 58 known families worldwide affected by this rare DNM1L-related disorder.
Background
This case highlights the challenges in diagnosing rare genetic disorders, where initial symptoms may be misinterpreted as common conditions like cerebral palsy. The involvement of the Undiagnosed Diseases Network and academic researchers, such as Michael Wangler at Baylor College of Medicine, underscores the importance of collaborative, long-term medical investigations in identifying novel genetic causes. The use of model organisms like fruit flies to validate human genetic variants is a growing trend in precision medicine, allowing researchers to confirm the pathogenicity of mutations that were previously considered benign or of unknown significance.
Why it matters
The story of Oliver Broner illustrates the critical need for persistent advocacy by families in the face of medical uncertainty and the value of advanced genetic testing in resolving complex pediatric cases. It also highlights the importance of re-evaluating previously dismissed genetic variants, as new research can change their clinical significance. The establishment of a foundation for DNM1L-related disorders may accelerate research and support for the small but growing community of affected families, potentially leading to better treatments and earlier diagnoses in the future.
What to watch
The Broner family’s foundation will continue to raise funds for research and connect the 58 known cases of DNM1L-related disorders worldwide. As more cases are identified and studied, researchers may gain a better understanding of the spectrum of symptoms associated with different variants of the gene. Oliver, now in ninth grade, will continue to manage his condition with medication and assistive devices, while his family advocates for greater awareness and support for rare genetic disorders.
Want the full story? Read the original reporting
Read on The Washington Post